When Can Nutritional Therapy Impact Liver Disease?

Current Gastroenterology Reports

Volumn 16, Issue 10, 2014, Pages 1-7

  Bozeman, Matthew C ^a   Benns, Matthew V ^a   McClave, Stephen A ^a   Miller, Keith R ^a   Jones, Christopher M ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Liver failure; Liver transplant; Malnutrition; Sarcopenia

Indexed keywords

ISOLEUCINE; LACTULOSE; LEUCINE; PREBIOTIC AGENT; PROBIOTIC AGENT; TRACE ELEMENT; VALINE; ZINC;

CARBOHYDRATE DIET; DIET SUPPLEMENTATION; FOOD INTAKE; HUMAN; LIVER DISEASE; LIVER FAILURE; MALNUTRITION; MUSCLE ATROPHY; NUTRITIONAL ASSESSMENT; NUTRITIONAL REQUIREMENT; NUTRITIONAL SUPPORT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SARCOPENIA; COMPLICATION; DIET THERAPY; ELEMENTAL DIET;

DIETARY SUPPLEMENTS; FOOD, FORMULATED; HUMANS; LIVER DISEASES; LIVER FAILURE; MICRONUTRIENTS; NUTRITION ASSESSMENT; NUTRITIONAL REQUIREMENTS; SARCOPENIA;

EID: 84906721169     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-014-0411-3     Document Type: Review

References (73)

1. O’Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet. 1993;342:273–5.
2. Caregaro L, Alberino F, Amodio P, et al. Malnutrition in alcoholic and virus-related cirrhosis. Am J Clin Nutr. 1996;63:602–9.
3. Dudrick SJ, Kavic SM. Hepatobiliary nutrition: history and future. J Hepatobiliary Pancreat Surg. 2002;9:459–68.
4. Italian Multicentre Cooperative Project on Nutrition in Liver Cirrhosis. Nutritional status in cirrhosis. J Hepatol. 1994;21:317–25.
5. Carvalho L, Parise ER. Evaluation of nutritional status of nonhospitalized patients with liver cirrhosis. Arq Gastroenterol. 2006;43:269–74.
6. Altamirano J, Fagundes C, Dominguez M, et al. Acute kidney injury is an early predictor of mortality for patients with alcoholic hepatitis. Clin Gastroenterol Hepatol. 2012;10:65–71.
7. Tan BH, Birdsell LA, Martin L, et al. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res. 2009;15:6973–9.
8. van Vledder MG, Levolger S, Ayez N, et al. Body composition and outcome in patients undergoing resection of colorectal liver metastases. Br J Surg. 2012;99:550–7.
9. Sabel MS, Lee J, Cai S, et al. Sarcopenia as a prognostic factor among patients with stage III melanoma. Ann Surg Oncol. 2011;18:3579–85.
10. Montano-Loza AJ, Meza-Junco J, Prado CM, et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol. 2012;10:166–73. This study demonstrated only a very low level of association between scoring systems for liver disease and sarcopenia, as measured by CT scan at the third vertebral level. Length of survival and mortality were worse in patients with sarcopenia. A question raised by this study is whether sarcopenia should be included in conventional models of liver disease.
11. Englesbe MJ, Patel SP, He K, et al. Sarcopenia and mortality after liver transplantation. J Am Coll Surg. 2010;211:271–8.
12. Rosenberg I. Summary comments: epidemiological and methodological problems in determining nutritional status in older persons. Am J Clin Nutr. 1989;50:1231–3.
13. Delmonico MJ, Harris TB, Lee JS, et al. Alternative definitions of sarcopenia, lower extremity performance, and functional impairment with aging in older men and women. J Am Geriatr Soc. 2007;55:769–74.
14. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39:412–23.
15. Goodpaster BH, Park SW, Harris TB, et al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci. 2006;61:1059–64.
16. Rosenberg I. Sarcopenia: origins and clinical relevance. J Nutr. 1997;127:990S–1S.
17. Figueiredo FA, Dickson ER, Pasha TM, et al. Utility of standard nutritional parameters in detecting body cell mass depletion in patients with end-stage liver disease. Liver Transpl. 2000;6:575–81.
18. Sam J, Nguyen GC. Protein-calorie malnutrition as a prognostic indicator of mortality among patients hospitalized with cirrhosis and portal hypertension. Liver Int. 2009;29:1396–402.
19. Thuluvath PJ, Triger DR. Evaluation of nutritional status by using anthropometry in adults with alcoholic and nonalcoholic liver disease. Am J Clin Nutr. 1994;60:269–73.
20. Morgan MY, Madden AM, Jennings G, et al. Two-component models are of limited value for the assessment of body composition in patients with cirrhosis. Am J Clin Nutr. 2006;84:1151–62.
21. Morgan MY, Madden AM, Soulsby CT, et al. Derivation and validation of a new global method for assessing nutritional status in patients with cirrhosis. Hepatology. 2006;44:823–35.
22. Mourtzakis M, Prado CM, Lieffers JR, et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33:997–1006.
23. Norman K, Stobaus N, Pirlich M, et al. Bioelectrical phase angle and impedance vector analysis—clinical relevance and applicability of impedance parameters. Clin Nutr. 2012;31:854–61.
24. Tandon P, Ney M, Irwin I, et al. Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value. Liver Transpl. 2012;18:1209–16. A well done study describing the incidence of sarcopenia in the pre-transplant patient population which could serve as a model for future research into the role sarcopenia should play in determining organ allocation.
25. Krell RW, Kaul DR, Martin AR, et al. Association between sarcopenia and the risk of serious infection among adults undergoing liver transplantation. Liver Transpl. 2013;19:1396–402.
26. Alvares-da-Silva MR, Reverbel da Silveira T. Comparison between handgrip strength, subjective global assessment, and prognostic nutritional index in assessing malnutrition and predicting clinical outcome in cirrhotic outpatients. Nutrition. 2005;21:113–7.
27. Juakiem W, Torres DM, Harrison SA. Nutrition in cirrhosis and chronic liver disease. Clin Liver Dis. 2014;18:179–90.
28. Mathan LKE-SS. Krause’s food nutrition and diet therapy. Philadelphia: WB Saunders; 2000.
29. Plauth M, Cabre E, Riggio O, et al. ESPEN guidelines on enteral nutrition: liver disease. Clin Nutr. 2006;25:285–94.
30. Hasse J, Strong S, Gorman MA, et al. Subjective global assessment: alternative nutrition-assessment technique for liver-transplant candidates. Nutrition. 1993;9:339–43.
31. Grossberg AJ, Scarlett JM, Marks DL. Hypothalamic mechanisms in cachexia. Physiol Behav. 2010;100:478–89.
32. Aqel BA, Scolapio JS, Dickson RC, et al. Contribution of ascites to impaired gastric function and nutritional intake in patients with cirrhosis and ascites. Clin Gastroenterol Hepatol. 2005;3:1095–100.
33. Plauth M, Schutz ET. Cachexia in liver cirrhosis. Int J Cardiol. 2002;85:83–7.
34. Cheung K, Lee SS, Raman M. Prevalence and mechanisms of malnutrition in patients with advanced liver disease, and nutrition management strategies. Clin Gastroenterol Hepatol. 2012;10:117–25.
35. Tsiaousi ET, Hatzitolios AI, Trygonis SK, et al. Malnutrition in end stage liver disease: recommendations and nutritional support. J Gastroenterol Hepatol. 2008;23:527–33.
36. Vlahcevic ZR, Buhac I, Farrar JT, et al. Bile acid metabolism in patients with cirrhosis. I. Kinetic aspects of cholic acid metabolism. Gastroenterology. 1971;60:491–8.
37. Dam G, Ott P, Aagaard NK, et al. Branched-chain amino acids and muscle ammonia detoxification in cirrhosis. Metab Brain Dis. 2013;28:217–20.
38. American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors. Clinical guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients, 2009. JPEN J Parenter Enteral Nutr. 2009;33:255–9.
39. Tsien CD, McCullough AJ, Dasarathy S. Late evening snack: exploiting a period of anabolic opportunity in cirrhosis. J Gastroenterol Hepatol. 2012;27:430–41.
40. Vaisman N, Katzman H, Carmiel-Haggai M, et al. Breakfast improves cognitive function in cirrhotic patients with cognitive impairment. Am J Clin Nutr. 2010;92:137–40.
41. Matos C, Porayko MK, Francisco-Ziller N, et al. Nutrition and chronic liver disease. J Clin Gastroenterol. 2002;35:391–7.
42. Hammand A, Kaido T, Uemoto S. Perioperative nutritional therapy in liver transplantation. Surg Today. 2014. doi:10.1007/s00595-014-0842-3.
43. Pescovitz MD, Mehta PL, Jindal RM, et al. Zinc deficiency and its repletion following liver transplantation in humans. Clin Transplant. 1996;10:256–60.
44. Munoz SJ, Deems RO, Moritz MJ, et al. Hyperlipidemia and obesity after orthotopic liver transplantation. Transplant Proc. 1991;23:1480–3.
45. Janczewska I, Ericzon BG, Eriksson LS. Influence of orthotopic liver transplantation on serum vitamin A levels in patients with chronic liver disease. Scand J Gastroenterol. 1995;30:68–71.
46. Ozaki N, Ringe B, Gubernatis G, et al. Changes in energy substrates in relation to arterial ketone body ratio after human orthotopic liver transplantation. Surgery. 1993;113:403–9.
47. Palmer M, Schaffner F, Thung SN. Excessive weight gain after liver transplantation. Transplantation. 1991;51:797–800.
48. Holt RI, Broide E, Buchanan CR, et al. Orthotopic liver transplantation reverses the adverse nutritional changes of end-stage liver disease in children. Am J Clin Nutr. 1997;65:534–42.
49. Canzanello VJ, Schwartz L, Taler SJ, et al. Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus (FK506). Liver Transpl Surg. 1997;3:1–9.
50. Hasse J. Liver transplantation: the benefits of nutrition therapy in the liver transplant patient. Liver Transpl. 1996;2:81–100.
51. Shanbhogue RL, Bistrian BR, Jenkins RL, et al. Increased protein catabolism without hypermetabolism after human orthotopic liver transplantation. Surgery. 1987;101:146–9.
52. Kaido T, Ogawa K, Fujimoto Y, et al. Impact of sarcopenia on survival in patients undergoing living donor liver transplantation. Am J Transplant. 2013;13:1549–56. This work investigated the impact of sarcopenia and immunonutrition in liver transplant patients. Lean muscle mass was evaluated prior to transplant by BIA, and patients were fed immunomodulating formulas early in the perioperative period. Low lean muscle mass was independently associated with mortality, but the addition of early immunomodulating enteral feeds increased survival in patients with low skeletal mass. These results could allow for improved recipient selection, as well as illustrates the impact immunonutrition could play in these complex patients.
53. Kaido T, Mori A, Ogura Y, et al. Impact of enteral nutrition using a new immuno-modulating diet after liver transplantation. Hepatogastroenterology. 2010;57:1522–5.
54. Kaido T, Mori A, Oike F, et al. Impact of pretransplant nutritional status in patients undergoing liver transplantation. Hepatogastroenterology. 2010;57:1489–92.
55. Bode JC, Hanisch P, Henning H, et al. Hepatic zinc content in patients with various stages of alcoholic liver disease and in patients with chronic active and chronic persistent hepatitis. Hepatology. 1988;8:1605–9.
56. Hayashi M, Ikezawa K, Ono A, et al. Evaluation of the effects of combination therapy with branched-chain amino acid and zinc supplements on nitrogen metabolism in liver cirrhosis. Hepatol Res. 2007;37:615–9.
57. Takuma Y, Nouso K, Makino Y, et al. Clinical trial: oral zinc in hepatic encephalopathy. Aliment Pharmacol Ther. 2010;32:1080–90.
58. Loser C, Folsch UR. Guidelines for treatment with percutaneous endoscopic gastrostomy. German Society of Digestive and Metabolic Diseases. Z Gastroenterol. 1996;34:404–8.
59. Plank LD, McCall JL, Gane EJ, et al. Pre- and postoperative immunonutrition in patients undergoing liver transplantation: a pilot study of safety and efficacy. Clin Nutr. 2005;24:288–96.
60. Als-Nielsen B, Gluud LL, Gluud C. Nonabsorbable disaccharides for hepatic encephalopathy. Cochrane Database Syst Rev. 2004;2, CD003044.
61. Agrawal A, Sharma BC, Sharma P, et al. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am J Gastroenterol. 2012;107:1043–50.
62. Amodio P, Bemeur C, Butterworth R, et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology. 2013;58:325–36.
63. McGee RG, Bakens A, Wiley K et al. Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst Rev 2011;CD008716.
64. Holecek M. Three targets of branched-chain amino acid supplementation in the treatment of liver disease. Nutrition. 2010;26:482–90.
65. Paul HS, Adibi SA. Activation of hepatic branched chain alpha-keto acid dehydrogenase by a skeletal muscle factor. J Biol Chem. 1982;257:12581–8.
66. Damuni Z, Merryfield ML, Humphreys JS, et al. Purification and properties of branched-chain alpha-keto acid dehydrogenase phosphatase from bovine kidney. Proc Natl Acad Sci U S A. 1984;81:4335–8.
67. Rose CF. Ammonia-lowering strategies for the treatment of hepatic encephalopathy. Clin Pharmacol Ther. 2012;92:321–31.
68. Skowronska M, Albrecht J. Alterations of blood brain barrier function in hyperammonemia: an overview. Neurotox Res. 2012;21:236–44.
69. Yamamoto M, Iwasa M, Matsumura K, et al. Improvement of regional cerebral blood flow after oral intake of branched-chain amino acids in patients with cirrhosis. World J Gastroenterol. 2005;11:6792–9.
70. Marchesini G, Bianchi G, Merli M, et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology. 2003;124:1792–801.
71. Muto Y, Sato S, Watanabe A, et al. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol. 2005;3:705–13.
72. Nakaya Y, Okita K, Suzuki K, et al. BCAA-enriched snack improves nutritional state of cirrhosis. Nutrition. 2007;23:113–20.
73. Metcalfe EL, Avenell A, Fraser A. Branched-chain amino acid supplementation in adults with cirrhosis and porto-systemic encephalopathy: systemic review. Clin Nutr. 2014. doi:10.1016/j.clnu.2014.02.011.